Description
ACSL could provide Icosapent ethyl (EPA-EE *6% plus) as API for
Epadel or Vascepa and the quality is well beyond JP standard with
annual capacity of **0 tons.
Vascepa is developed by Amarin Corporation; it is Amarin's first
FDA approved product, marketed at US market.
Vascepa is a prescription-grade omega*3 fatty acid, comprising
polyunsaturated fatty acids ultra pure EPA (Icosapent Ethyl) not
less than *6%.
It is cardiovascular drug to reduce blood fats known as
triglycerides for the treatment of patients with very high
triglyceride levels and the treatment of patients with high
triglycerides with mixed dyslipidemia.
Vascepa API (Icosapent Ethyl)
Vascepa is developed by Amarin Corporation; it is Amarin's first
FDA approved product, marketed at US market.
Vascepa is a prescription-grade omega*3 fatty acid, comprising
polyunsaturated fatty acids ultra pure EPA (Icosapent Ethyl) not
less than *6%.
It is cardiovascular drug to reduce blood fats known as
triglycerides for the treatment of patients with very high
triglyceride levels and the treatment of patients with high
triglycerides with mixed dyslipidemia.
Epadel API (Icosapent Ethyl)
Epadel is an OTC drug developed by Machida and market at Japan for
near *0 years. It also comprises of ultra pure EPA (Icosapent
Ethyl) not less than *6%.
ACSL has unique purification processes technology, could provide
large quantity API grade of Icosapent Ethyl.
